PPARs, insulin resistance and type 2 diabetes

European Journal of Cardiovascular Prevention & Rehabilitation

Volumn 8, Issue 4, 2001, Pages 211-217

  Kaplan, Felicity ^a   al Majali, Khulood ^a   Betteridge, D John ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; ANTIDIABETIC AGENT; CELL RECEPTOR; THIAZOLE DERIVATIVE; TRANSCRIPTION FACTOR;

CARDIOVASCULAR RISK; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; DRUG POTENTIATION; HYPERLIPIDEMIA; METABOLIC SYNDROME X; METABOLISM; PHYSIOLOGY;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METABOLIC SYNDROME X; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; TRANSCRIPTION FACTORS;

EID: 0034741948     PISSN: 17418267     EISSN: 17418275     Source Type: Journal    
DOI: 10.1177/174182670100800405     Document Type: Article

References (64)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025 Prevalence, numerical estimates and projections. Diabetes Care 1998; 21: 1414–1431.
2. Zimmet PZ, Alberti K.G.M.M., The changing face of macrovascular disease in non-insulin dependent diabetes mellitus: An epidemic in progress. Lancet 1997; 350 (suppl 1):1–4.
3. Nathan DM, Meigs J, Singer DE. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: How sweet it is … or is it? Lancet 1997; 350 (suppl 1):S14–S19.
4. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853.
5. Yki-Jarvinen H. Evidence for a primary role of insulin resistance in the pathogenesis of type 2 diabetes. Ann Med 1990; 22: 197–200.
6. Eriksson J, Franssila-Kallunki A, Ekstrand A, Saloranto C, Widen E, Schalin C, Groop L. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989; 321: 337–343.
7. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (Syndrome X). Diabetes 1992; 41: 715–722.
8. Reaven GM. Banting Lecture 1988 Role of insulin in human disease. Diabetes 1988; 37: 1595–1607.
9. Haffner SM, Miettinen H. Insulin resistance implications for type 2 diabetes mellitus and coronary heart disease. Am J Med 1997; 103: 152–162.
10. American Diabetes Association. Consensus Development Conference on Insulin Resistance. Diabetes Care 1998; 21: 310–314.
11. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, et al Insulin sensitivity and atherosclerosis. Circulation 1996; 93: 1809–1817.
12. Lehto S, Ronnemaa T, Pyorala K, Laakso M. Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with type 2 diabetes. Diabetologia 2000; 43: 148–155.
13. Schwartz MW, Kahn SE. Insulin resistance and obesity. Nature 1999; 402: 860–861.
14. Schoonjans K, Auwerx J. Thiazolidinediones: An update. Lancet 2000; 355: 1008–1010.
15. Desvergne B, Wahli W. Peroxisome proliferator-activity receptors: Nuclear control of metabolism. Endocrinol Rev 1999; 20: 649–688.
16. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 2000; 106: 467–472.
17. Lowell BB. PPARgamma an essential regulator of adipogenesis and modulator of fat cell function. Cell 1999; 99: 230–253.
18. Auwerx J, Mangelsdorf D. Atherosclerosis XII. In: Stemme S, Olsson AG, editors. Excerpta Medica. International Congress Series 1215. Amsterdam: Elsevier; 2000. pp. 21–39.
19. Miles PDG, Barak Y, He W, Evans RM, Olefsky JM. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest 2000; 105: 287–292.
20. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, et al PPARgamma mediates high fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999; 4: 597–609.
21. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutations in a genetic regulator of adipocyte differentiation. N Engl J Med 1998; 339: 953–959.
22. Barroso I, Gurnell M, Crowley VEF, Agostini M, Schwabe JW, Soos MA, et al Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402: 880–883.
23. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidised LDL. Cell 1998; 93: 241–252.
24. Ricote M, Huang J, Fajas L, Welch LA, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidised low density lipoprotein. Proc Natl Acad Sci USA 1998; 95: 7614–7619.
25. Marx N, Schoenbeck U, Lazar MA, Lippy P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibitor gene expression and migration in human vascular smooth muscle cells. Circ Res 1998; 83: 1097–1103.
26. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45: 1661–1669.
27. Ibrahimi A, Teboul L, Gaillard D, Amri EZ, Ailhaud G, Young P, et al Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in pre-adipose cells. Mol Pharmacol 1994; 46: 1070–1076.
28. Fonseca VA, Reynolds T, Hemphill D, Randolph C, Wall J, Valiquet TR, et al Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 1998; 12: 181–186.
29. Horton ES, Whitehouse F, Ghazzi MN, Venable TC, Whitcomb RW. Troglitazone in combination with sulphonylurea restores glycaemic control in patients with type 2 diabetes. Diabetes Care 1998; 21: 1462–1469.
30. Buse J, Gumbiner B, Mathias NP, Nelson DM, Faja BW, Whitcomb RW. Troglitazone use in insulin treated type 2 diabetic patients. Diabetes Care 1998; 21: 1455–1461.
31. Schwartz S, Raskin P, Fonseca V, Graveline J. Effect of troglitazone in insulin-treated patients with type 2 diabetes mellitus. N Engl J Med 1998; 338: 861–866.
32. Suter S, Nolan J, Wallace P, Gumbiner B, Olefsky JM. Metabolic effects of a new oral hypoglycaemia agent CS-045 in non insulin dependent diabetic subjects. Diabetes Care 1992; 15: 193–203.
33. Sunayama S, Watanabe Y, Daida H, Yamaguchi O. Thiazolidinediones, dyslipidaemia and insulin resistance syndrome. Curr Opin Lipidol 2000; 11: 397–402.
34. Tack CJ, Smits P, Demacker PN, Stalenhoef AF. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 1998; 21: 796–799.
35. Hirano T, Yoshino G, Kazumi T. Troglitazone and small low density lipoprotein in type 2 diabetes. Ann Int Med 1998; 129: 162–163.
36. Shirai K, Itoh Y, Sasaki H, Totsuka M, Murano T, Watanabe H, Miyashita Y. The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in postheparin serum. Diabetes Res Clin Pract 1999; 46: 35–41.
37. Sunayama S, Watanabe Y, Ohmura H, Sawano M, Shimada K, Mokuno H, et al Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. Atherosclerosis 1999; 146: 187–193.
38. Matsumoto K, Miyake S, Yano M, Ueki Y, Tominaga Y. Increase of lipoprotein(a) with troglitazone. Lancet 1997; 350: 1748–1749.
39. Ovalle F, Bell DS. Troglitazone's effect on lipoprotein(a) levels. Diabetes Care 1999; 22: 859–860.
40. Ishizuka T, Itaya S, Wada H, Ishizawa M, Kimura M, Kajita K, et al Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism. Diabetes 1998; 47: 1494–1500.
41. Ebeling P, Teppo AM, Koistinen HA, Viikari J, Ronnemaa T, Nissen M, et al Troglitazone reduces hyperglycaemia and selectivity acute-phase serum proteins in patients with type 2 diabetes. Diabetologia 1999; 42: 1433–1438.
42. Ogihara T, Takugi H, Ikegami H, Mikami H, Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995; 8: 316–320.
43. Imano E, Kanda T, Nakatani Y, Nishida T, Arai K, Motomura M, et al Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998; 21: 2135–2139.
44. Martin G, Schoonjans K, Staels B, Auwerx J. PPARgamma activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis 1998; 137 (suppl 1):S75–S80.
45. Spiegelman BM. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507–514.
46. Kobayashi J, Nagashima I, Hikita M, Bujo H, Takahashi K, Otabe M, et al Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase. Br J Clin Pharmacol 1999; 47: 433–439.
47. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, et al PPAR alpha and PPAR gamma activators direct a distinct tissue-specific transcriptional message via a PPRE in the lipoprotein lipase gene. EMBO J 1996; 15: 5336–5348.
48. Lefebvre AM, Peinado-Onsurbe J, Leitersdorf I, Briggs MR, Paterniti JR, Fruchart JC, et al Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Atheroscl Thromb Vasc Biol 1997; 17: 1756–1764.
49. Kelly IE, Han TS, Walsh K, Lean ME. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22: 288–293.
50. Tontonoz P, Nagy L. Regulation of macrophage gene expression by peroxisome-proliferator-activated receptor gamma: Implications for cardiovascular disease. Curr Opin Lipidol 1999; 10: 485–490.
51. Law RE, Mechan WP, Xi X-P, Graf K, Wuthrich DA, Coats W, et al Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996; 98: 1897–1905.
52. Shiomi M, Ito T, Tsukada T, Tsujita Y, Horikoshi H. Combination treatment with troglitazone, an insulin action enhancer, and pravastatin an inhibitor of HMG CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits. Atherosclerosis 1999; 142: 345–353.
53. Minamikawa J, Tanaka S, Yamamuchi M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998; 83: 1818–1820.
54. Day C. Thiazolidinediones: A new class of antidiabetic drugs. Diabetic Med 1999; 16: 179–192.
55. Scheen AJ, Lefebvre PJ. Troglitazone: Antihyperglycaemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care 1999; 22: 1568–1577.
56. Camp HS, Li O, Wise SC, Hong YH, Frankowski CL, Shen X, et al Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes 2000; 49: 539–547.
57. Krentz AJ, Bailey CJ, Melander A. Thiazolidinediones for type 2 diabetes. New Agents reduce insulin resistance but need long term clinical trials. Br Med J 2000; 321: 252–253.
58. Freid J, Everitt D, Boscia J. Rosiglitazone and hepatic failure. Ann Intern Med 2000; 132: 164.
59. Al-Salman J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med 2000; 132: 121–124.
60. National Institute for Clinical Excellence. Guidance on rosiglitazone for type 2 diabetes mellitus. Technology appraisal guidance No. 9 London; 2000.
61. Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonlurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000; 17: 40–47.
62. Li AC, Brown KK, Sibestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000; 106: 523–531.
63. Lawrence J, Reckless JPD. Pioglitazone. Int J Clin Pract 2000; 54: 614–618.
64. Rubens HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al For the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med 1999; 341: 410–418.